ERBB2 and neoplasm: Independently of the molecular origin, NAC-induced loss of HR expression can have clinically relevant consequences; indeed, while the assessment of HR and HER2 status in CNBs is essential to guide the choice of preoperative treatments, biological tumor re-characterization after systemic neoadjuvant treatment in those patients failing to achieve pCR is essential for guiding post-surgical treatment planning.